ER
UTHR icon

Enlightenment Research’s United Therapeutics UTHR Stock Holding History

Enlightenment Research’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,500
Closed -$256K – 273
2019
Q2 		$256K Buy
+2,500
New +$234K 0.13% 200

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Enlightenment Research's UTHR Position: Q3 2019 in Review

Enlightenment Research sold out of United Therapeutics (UTHR) in Q3 2019, closing a stake of 2,500 shares — an estimated $256K sold.

Enlightenment Research first reported a position in UTHR in Q2 2019 and held it in 1 quarter. The position peaked at $256K in Q2 2019. 302 funds tracked by Wall St. Rank hold UTHR as of Q3 2019.

  • Enlightenment Research reported no remaining United Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Enlightenment Research sold 2,500 United Therapeutics shares in Q3 2019, an estimated $256K.
  • Enlightenment Research first reported a position in United Therapeutics in Q2 2019 and held it in 1 quarter.
  • Enlightenment Research's United Therapeutics position peaked at $256K in Q2 2019.
  • 302 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2019.

Based on Enlightenment Research's 13F filing for Q3 2019, filed 16 Oct 2019.